Dipyridamole sustained-release capsules

It has anti-thrombotic effect. Dipyridamole inhibits platelet aggregation, and high concentrations can inhibit platelet release. The mechanism of action may be: 1. Inhibits the uptake of adenosine by platelets, epithelial cells and erythrocytes. The inhibitory effect is dose-dependent at therapeutic concentrations (0.5-1.9 μg/dl). The local adenosine concentration increases, acting on the A2 receptor of platelets, stimulating adenylate cyclase and increasing cyclic adenosine monophosphate in platelets. Through this pathway, platelet aggregation caused by stimulation of platelet activating factor, collagen and adenosine diphosphate is inhibited; 2. Inhibits phosphodiesterase in various tissues. The therapeutic concentration inhibits cyclic guanosine monophosphate phosphodiesterase, thereby enhancing the increase in CGMP concentration caused by endothelial relaxing factor; 3. Inhibits the formation of thromboxane A2 (TXA2), which is a strong agonist of platelet activity; 4. Enhances the effect of endogenous PGI2. Dipyridamole has a dilating effect on blood vessels. Intraduodenal administration of dipyridamole at a dose of 0.5 to 4.0 mg/kg produced dose-related decreases in systemic and coronary vascular resistance, lower systemic blood pressure, and increased coronary blood flow in dogs. The effect started 24 minutes after administration and lasted for about 3 hours. The same hemodynamic effects were observed in humans. However, acute intravenous administration can reduce local myocardial perfusion distal to the stenotic coronary artery. In oral studies of mice for 111 weeks and rats for 128 to 142 weeks, 8, 25, and 75 mg/kg (1, 3.1, and 9.4 times the maximum recommended daily dose for humans) of dipyridamole did not produce significant carcinogenic effects. The results of the mutagenicity test were negative. Rat reproduction studies using 60 times the maximum recommended daily dose of dipyridamole for humans showed no evidence of reproductive damage. However, at 115 times the maximum recommended daily dose for humans, the number of corpora lutea was significantly reduced and live fetal implantation was reduced. Studies on mice, rats, and rabbits showed no evidence of dipyridamole harming the fetus. The oral LD50 for mice is 2150 mg/kg; the single oral lethal dose for rats is 6000 mg/kg, and for dogs is 350 mg/kg.

The chemical name of this product is: 2,2prime;,2Prime;,2prime;prime;prime;-[(4,8-dipiperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)bis(nitrogen)-tetraethanol. Molecular formula: C24H40N8O4 Molecular weight: 504.63

This product is a sustained-release capsule containing yellow spherical pellets.

Prevention and treatment of thromboembolic disease, alone or in combination with aspirin.

Take 200 mg orally once, twice a day.

Adverse reactions are mild and short-lived at therapeutic doses, and the initial side effects usually disappear after long-term use. Common adverse reactions include dizziness, headache, vomiting, diarrhea, flushing, rash and itching, and rarely angina pectoris and liver dysfunction. Persistent or intolerable adverse reactions are rare and can be eliminated after stopping the drug.

It is contraindicated for those who are allergic to this product.

It has a synergistic effect with aspirin. It can cause bleeding tendency when used together with heparin. Bleeding does not increase or intensify when used together with dicoumarol anticoagulants.

Keep in a dark, airtight, cool place.

25 mg

NORTHEAST Pharmaceutical Group Shenyang NO.1 Pharmaceutical Co., Ltd.

• Founded in:

  1989-01-25

• Address:

  No. 8 Kunming Lake Street, Shenyang Economic and Technological Development Zone

• Tax NO.:

  91210106242656694M

• Registered Funds:

  80 million yuan

• Website:

  Log in to view

• Email:

  Log in to view